Epidermal growth factor receptor expression in ameloblastoma

Oral Oncology

Volumn 39, Issue 2, 2003, Pages 138-143

  Vered, Marilena ^a   Shohat, Izhar ^b   Buchner, Amos ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Ameloblastoma; Anti EGFR immunotherapy; EGFR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FORMALDEHYDE; MONOCLONAL ANTIBODY; PARAFFIN;

ADULT; AGED; AMELOBLASTOMA; ANTIBODY LABELING; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCORING SYSTEM; STAINING; TUMOR VOLUME;

ADULT; AGED; AMELOBLASTOMA; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; JAW NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PARAFFIN EMBEDDING; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 12244267967     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(02)00034-9     Document Type: Article

References (23)

1. Sciubba JJ, Fantasia JA, Kahn LB, editors, Benign odontogenic tumors. In: Atlas of Tumor Pathology - Tumors and Cysts of the Jaw. Washington, DC: AFIP, 1999. p. 71-85.
2. Neville BW, Damm DD, Allen CM. Odontogenic cysts and tumors. In: Gnepp DR, editor. Diagnostic Surgical Pathology of the Head and Neck. New York: Saunders, 2001. p. 622-33.
3. Waldron CA. Odontogenic cysts and tumors. In: Neville BW, Damm DD, Allen CM, Bouquot JE, editors. Oral and Maxillofacial Pathology. Philadelphia: Saunders, 1995. p. 512-22.
4. Bredenkamp J.K., Zimmerman M.C., Mickel R.A. Maxillary ameloblastoma. A potentially lethal neoplasm. Arch Otolaryngol Head Neck Surg. 115:1989;99-104.
5. Baselga J, O'Dwyer PJ, Thor AD, Vokes EE, Weiner LM. Epidermal Growth Factor Receptor: Potential Target for Antitumor Agents. Dallas, TX: The Center for Biomedical Continuing Education, 2000. p. 1-24.
6. Shrestha P., Yamada K., Higashiyama H., Takagi H., Mori M. Epidermal growth factor receptor in odontogenic cysts and tumors. J Oral Pathol Med. 21:1992;314-317.
7. Jost M., Kari C., Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol. 10:2000;505-510.
8. γ and the epidermal growth-factor, platelet-derived growth-factor and fibroblast growth-factor receptors in the cells of the rat molar enamel organ during early amelogenesis. Arch Oral Biol. 44:1999;771-780.
9. Heikinheimo K., Voutilainen R., Happonen R.-P., Miettinen P.J. EGF receptor and its ligands, EGF and TGF-α, in developing and neoplastic human odontogenic tissues. Int J Dev Biol. 37:1993;387-396.
10. Li T.-J., Browne R.M., Matthews J.B. Expression of epidermal growth factor receptors by odontogenic jaw cysts. Virchows Arch A Pathol Anat Histopathol. 423:1993;137-144.
11. Ueno S., Miyagawa T., Kaji R., Mushimoto K., Shirasu R. Immunohistochemical investigation of epidermal growth factor receptor expression in ameloblastomas. J Pathol. 173:1994;33-38.
12. Nouri A.M.E., Cannell H., Ong'uti M., Tezabwala B.U., Oliver R.T.D. The possible relevance of the expression of MHC antigens and of EGF receptor in aggressive oral tumours. Int J Oncol. 10:1997;1217-1222.
13. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19:1995;183-232.
14. Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 82:1999;241-250.
15. Kramer IRH, Pindborg JJ, Shear M. Histological Typing of Odontogenic Tumors. WHO International Histological Classification of Tumors. Berlin: Springer-Verlag, 1992. p. 12-14.
16. Partridge M., Gullick W.J., Langdon J.D., Sherriff M. Expression of epidermal growth factor receptor on oral squamous cell carcinoma. Br J Oral Maxillofac Surg. 26:1988;381-389.
17. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer. 8:2001;3-9.
18. Slichenmyer W.J., Fry D.W. Anticancer therapy targeting the ErbB family of receptor tyrosine kinases. Semin Oncol. 28(suppl. 16):2001;67-79.
19. Dancey J.E., Schoenfeldt M. Clinical trials - referral resource. Epidermal growth factor receptor inhibitors in clinical trials. Oncology (Huntingt). 15:2001;748-758.
20. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer. 37:2001;S16-22.
21. Albanell J., Rojo F., Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol. 28(suppl. 16):2001;56-66.
22. Bue P., Holmberg A.R., Marquez M., Westlin J.-E., Nilsson S., Malmstrom P.U. Intravesical administration of EGF-dextran conjugates in patients with superficial bladder cancer. Eur Urol. 38:2000;84-89.
23. Yang X.-D., Jia X.-C., Corvalan J.R.F., Wang P., Davis G.C. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 38:2001;17-23.